Kopran Ltd. | Income Statement

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
Sales/Revenue
2,951
3,185
2,963
3,097
3,147
Cost of Goods Sold (COGS) incl. D&A
2,423
2,712
2,399
2,432
2,288
Gross Income
528
473
564
666
859
SG&A Expense
301
318
322
374
640
EBIT
219
150
-
280
219
Unusual Expense
-
543
11
1
-
Non Operating Income/Expense
90
130
5
101
96
Interest Expense
145
130
126
137
86
Pretax Income
172
391
107
250
229
Income Tax
-
-
-
2
24
Consolidated Net Income
172
391
107
248
205
Net Income
172
391
107
248
205
Net Income After Extraordinaries
172
391
107
248
205
Net Income Available to Common
172
391
107
248
205
EPS (Basic)
4.40
9.84
2.59
5.73
4.75
Basic Shares Outstanding
39
40
41
43
-
EPS (Diluted)
4.40
9.84
2.59
5.73
-
Diluted Shares Outstanding
39
40
41
43
-
EBITDA
348
246
315
364
304
Other Operating Expense
7
5
8
11
-
Non-Operating Interest Income
7
2
5
5
-

About Kopran

View Profile
Address
Parijat House
Mumbai Maharashtra 400018
India
Employees -
Website http://www.kopran.com
Updated 09/14/2018
Kopran Ltd. engages in the development and manufacture of pharmaceuticals and pharmaceutical ingredients. It operates through the following business units: Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development. The Finished Dosage Forms provides dosage forms such as tablets, capsules, dry powder, suspension and injectables.